Teva gets FDA approval of asthma drug Cinqair

24 March 2016
2019_biotech_test_vial_discovery_big

The US Food and Drug Administration has approved Cinqair (reslizumab) Injection, an interleukin 5 antagonist monoclonal antibody (IgG4 kappa) indicated for add-on maintenance treatment of patients with severe asthma aged 18 years and older, and with an eosinophilic phenotype.

Cinqair, from Israeli drugmaker Teva Pharmaceutical Industries (NYSE: TEVA), is administered by intravenous (IV) infusion at a weight-based dose of 3mg/kg once every four weeks. The treatment is expected to become commercially available to patients, by prescription, during the second quarter of 2016, the company said. This is the first ever approval of the drug.

The market for asthma treatments will remain relatively flat, increasing slightly from $15.9 billion in 2014 to $16.2 billion in 2024 across the seven major markets (the USA, France, Germany, Italy, Spain, the UK, and Japan), according to a recent report from Decision Resources.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology